Hester Biosciences Ltd

Hester Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 September 2026, providing investors with the latest insights into its fundamentals, valuation, financial trends, and technical outlook.

Hester Biosciences Ltd has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish trend as of late August 2026. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s technical indicators present a complex picture, with bullish signals on longer-term charts contrasting with bearish pressures on weekly momentum metrics. This analysis delves into the latest technical parameters, price movements, and comparative returns to provide a comprehensive view of the stock’s current market stance.

Hester Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 August 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with the most up-to-date insight into the company’s fundamentals, valuation, financial trends, and technical outlook.

Hester Biosciences Ltd., one of India's pioneering animal healthcare companies, has reported a remarkable 489.90% year-on-year surge in consolidated net profit to ₹96.98 crores for Q1 FY27, driven by an extraordinary one-time gain that inflated pre-tax profit to ₹101.68 crores. However, the underlying operational picture reveals concerning trends, with net sales declining 8.17% year-on-year to ₹77.24 crores and falling 22.84% sequentially from Q4 FY26's ₹100.11 crores. The stock, currently trading at ₹2,461.35 with a market capitalisation of ₹2,137 crores, has declined 1.30% following the results announcement, reflecting investor scepticism about the sustainability of this profit performance.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a notable shift from its previously positive growth trajectory. Despite robust profit after tax growth and strong return on capital employed, the company faces headwinds from declining sales and margin contraction, prompting a downgrade in its Mojo Grade from Hold to Sell.

Surging past its previous peaks, Hester Biosciences Ltd touched a fresh 52-week high of Rs 2669 on 30 Jul 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and a market environment where the Sensex trades near its own highs.

Hester Biosciences Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 08 June 2026. While this rating change occurred in early June, the analysis and financial metrics discussed here reflect the company’s current position as of 23 July 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Surging past Rs 2660, Hester Biosciences Ltd has reached a fresh 52-week high on 14 Jul 2026, marking a significant milestone in its price momentum. This rally has been underpinned by a confluence of bullish technical indicators and sustained gains over the past four sessions, even as the broader Sensex trades lower.

At Rs 2,545, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Hester Biosciences Ltd locked at its upper circuit of 20% on 13 Jul 2026, with buyers queuing and no sellers willing to part with shares.

With a decisive surge to Rs 2399.3 on 13 Jul 2026, Hester Biosciences Ltd has marked a new 52-week high, extending its impressive 33.9% gain over the past year. This rally stands out amid a broadly subdued market backdrop, underscoring the stock’s strong technical momentum and sustained buying interest.

Hester Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 July 2026, providing investors with the latest insights into its performance and outlook.

Hester Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 June 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 01 July 2026, providing investors with the latest comprehensive analysis.

Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently seen its quality grade downgraded from average to below average by MarketsMOJO as of 8 June 2026. This shift reflects a nuanced change in the company’s underlying business fundamentals, including key metrics such as return on equity (ROE), return on capital employed (ROCE), debt levels, and growth consistency. This article delves into these parameters to assess what has improved and what has deteriorated, providing investors with a comprehensive understanding of the company’s current standing.